Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/57198
Type
ArticleCopyright
Open access
Collections
- INI - Artigos de Periódicos [3384]
Metadata
Show full item record
THE IMPACT OF COVID-19 ON HIV CARE IN RIO DE JANEIRO, BRAZIL 2019-2021: DISPARITIES BY AGE AND GENDER
Author
Affilliation
University of California. David Geffen School of Medicine. South American Program in HIV Prevention Research. Los Angeles, CA, USA / The Warren Alpert Medical School of Brown University. Providence, RI, USA.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
University of California. David Geffen School of Medicine. South American Program in HIV Prevention Research. Los Angeles, CA, USA / UTHealth Houston. Houston, TX, USA.
University of California. David Geffen School of Medicine. South American Program in HIV Prevention Research. Los Angeles, CA, USA / University of California. Center for HIV Identification, Prevention, and Treatment Services. Department of Family Medicine. Los Angeles, CA, USA.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. STD and AIDS Clinical Research Laboratory. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
University of California. David Geffen School of Medicine. South American Program in HIV Prevention Research. Los Angeles, CA, USA / UTHealth Houston. Houston, TX, USA.
University of California. David Geffen School of Medicine. South American Program in HIV Prevention Research. Los Angeles, CA, USA / University of California. Center for HIV Identification, Prevention, and Treatment Services. Department of Family Medicine. Los Angeles, CA, USA.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. STD and AIDS Clinical Research Laboratory. Rio de Janeiro, RJ, Brazil.
Abstract
We evaluated COVID-19's impact on HIV care indicators among INI/FIOCRUZ's HIV Clinical Cohort in Rio de Janeiro, Brazil: (1) Adequate care visits: two visits ≥ 90 days apart; (2) Adequate viral load monitoring: ≥ 2 viral load results ≥ 90 days apart; (3) Consistent viral suppression: all viral loads < 40 copies/mL; and (4) ART medication possession ratio (MPR) ≥ 95%. Chi-square tests compared the fraction of participants meeting each indicator per period: pre-pandemic (3/1/2019-2/29/2020) and post-pandemic (3/1/2020-2/28/2021). Logistic regression models were used to assess disparities in adequate care visits. Among 906 participants, care visits and viral load monitoring decreased pre-pandemic to post-pandemic: 77.0-55.1% and 36.6-11.6% (both p < 0.001), respectively. The optimal MPR rate improved from 25.5 to 40.0% (p < 0.001). Post-pandemic period (aOR 0.33, CI 0.28-0.40), transgender women (aOR 0.34, CI 0.22-0.53), and those aged 18-24 years (aOR 0.67, CI 0.45-0.97) had lower odds of adequate care visits. COVID-19 disrupted care access disproportionately for transgender women and younger participants.
Share